Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

The American Cancer Society has released updated prostate cancer screening guidelines, recommending biennial PSA screening for average-risk men aged 50–69 and annual screening starting at 45 for Black men and those with a strong family history. Clinicians are urged to have informed conversations about benefits and harms before screening begins. The guidelines also set specific PSA thresholds that should trigger further evaluation.
The American Cancer Society has published updated prostate cancer screening guidelines in CA: A Cancer Journal for Clinicians, offering more nuanced, risk-stratified recommendations aimed at catching advanced disease earlier while minimizing unnecessary treatment harms. Before any screening begins, clinicians are expected to walk patients through the benefits, limitations, and potential harms — including what happens if PSA levels come back elevated and the likelihood that low-risk cancers will be managed with active surveillance rather than immediate treatment.
The new guidelines tailor screening frequency and start age to individual risk profiles, with a particular emphasis on Black men and those with a strong family history, who face a higher risk of aggressive disease.
Key Takeaways:
Why it matters: These updates give clinicians a clearer, more personalized roadmap for prostate cancer screening — one that could help prevent late-stage diagnoses and premature deaths while reducing the risk of overtreatment in lower-risk patients.